tirzepatide peptide sequence is an antidiabetic medication used to treat type 2 diabetes and for weight loss - Tirzepatidepharmacokinetics peptide sequence

Tirzepatidepharmacokinetics The Peptide Sequence of Tirzepatide: A Detailed Exploration

Tirzepatide, a groundbreaking therapeutic agent, has garnered significant attention for its dual action as a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Understanding the intricate peptide sequence known as the tirzepatide peptide sequence is crucial to appreciating its efficacy and novel mechanism of action. This sequence is the foundation upon which its therapeutic properties are built, making it an indispensable aspect for researchers and healthcare professionals alike.

At its core, Tirzepatide is a synthetic peptide comprising a 39 amino acid linear peptide chain.CN110903355A - Preparation method of Tirzepatide The peptide sequence is presented in a familiar one-letter code, offering a concise representation of its structure.Overview of Tirzepatide and Semaglutide While the exact full sequence is extensive, a representative portion is often cited as YXEGTFTSDYSIXLDKIAQKAFVQWLIAGGPSSGAPPPS. This specific arrangement of amino acids dictates how tirzepatide interacts with its target receptors.

A key feature contributing to tirzepatide's unique profile are the two non-coded amino acid residues at positions 2 and 13. These are identified as Aib, or alpha-aminoisobutyric acid. The incorporation of these non-canonical amino acids plays a significant role in enhancing the molecule's stability and prolonging its half-life, a critical factor for a medication administered through subcutaneous injections. This modification is a deliberate design choice that differentiates it from native peptides.

Furthermore, Tirzepatide's amino acid sequence is not a simple replication of naturally occurring hormones. It is described as a chimera, skillfully integrating elements from both native human GIP and GLP-1. This intelligent design, combined with specific modifications, allows tirzepatide to achieve a dual-target engagement. The molecule is further modified by conjugation to a C20 fatty diacid moiety via a linker, typically attached to a lysine residue. This lipidation is essential for binding to albumin, further extending its duration of action.

The peptide nature of tirzepatide is complemented by an amidated C-terminus, a common modification in peptide therapeutics that can influence stability and receptor interaction.作者：VP Chavda·2022·被引用次数：242—Thepeptide sequenceoftirzepatidecontains two non-coded amino acid residues (Aib, α-amino isobutyric acid) at position 2 and 13, which are responsible ... The overall sequence and its strategic modifications are meticulously crafted by Eli Lilly and Company, the originator of this innovative drug.

As a synthetic peptide, tirzepatide is recognized as an antidiabetic medication used not only to treat type 2 diabetes but also for weight loss. Its ability to selectively bind and activate both GIP and GLP-1 receptors is the underlying principle of its therapeutic benefits, supporting blood glucose management and contributing to weight reduction.

In summary, the tirzepatide peptide sequence is a complex yet elegant molecular construct. The precise arrangement of its 39 constituent amino acids, including the unique presence of two non-coded amino acid residues at positions 2 and 13, along with crucial modifications like the C20 fatty diacid conjugation, underpins its dual receptor agonism and therapeutic efficacy.CN110903355A - Preparation method of Tirzepatide This detailed understanding of the peptide sequence is fundamental to grasping the scientific advancements represented by tirzepatideStructurally it is39 amino acid linear peptidethat is conjugated to a C20 fatty diacid moiety by a linker connected to the lysine20 residue. The dual agonist ....